The obesity drug Mounjaro has now overtaken the blood thinner Eliquis as the best-selling drug in Swedish pharmacies, writes Dagens Medicin . This is despite the fact that users have to pay the relatively high costs themselves.
According to new figures from the Swedish E-Health Agency, sales during November amounted to SEK 157.3 million.
Mounjaro, which is manufactured by the American Eli Lilly and is injected, costs the patient around SEK 2,700 for a four-week treatment. It contributes to weight reduction and weight control by reducing the patient's feeling of hunger and has also been previously approved for the treatment of type 2 diabetes.
